Literature DB >> 29729104

The impact of diet-induced hepatic steatosis in a murine model of hepatic ischemia/reperfusion injury.

Kim H H Liss1, Kyle S McCommis2, Kari T Chambers2, Terri A Pietka2, George G Schweitzer2, Sara L Park2, Ilke Nalbantoglu3, Carla J Weinheimer2, Angela M Hall2, Brian N Finck2.   

Abstract

The prevalence of obesity-associated nonalcoholic fatty liver disease has significantly increased over the past decade, and end-stage liver disease secondary to nonalcoholic steatohepatitis has become 1 of the most common indications for liver transplantation. This both increases the demand for organs and decreases the availability of donor livers deemed suitable for transplantation. Although in the past many steatotic livers were discarded due to concerns over enhanced susceptibility to ischemia/reperfusion injury (IRI) and organ failure, the discrepancy between supply and demand has resulted in increasing use of expanded criteria donor organs including steatotic livers. However, it remains controversial whether steatotic livers can be safely used for transplantation and how best to improve the performance of steatotic grafts. We aimed to evaluate the impact of diet-induced hepatic steatosis in a murine model of IRI. Using a diet of high trans-fat, fructose, and cholesterol (HTF-C) and a diet high in saturated fats, sucrose, and cholesterol (Western diet), we were able to establish models of mixed macrovesicular and microvesicular steatosis (HTF-C) and microvesicular steatosis (Western). We found that the presence of hepatic steatosis, whether it is predominantly macrovesicular or microvesicular, significantly worsens IRI as measured by plasma alanine aminotransferase levels and inflammatory cytokine concentration, and histological evaluation for necrosis. Additionally, we report on a novel finding in which hepatic IRI in the setting of steatosis results in the induction of the necroptosis factors, receptor interacting protein kinase (RIPK) 3, RIPK1, and mixed-lineage kinase domain-like. These data lay the groundwork for additional experimentation to test potential therapeutic approaches to limit IRI in steatotic livers by using a genetically tractable system. Liver Transplantation 24 908-921 2018 AASLD.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 29729104      PMCID: PMC6097916          DOI: 10.1002/lt.25189

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  53 in total

1.  Mechanisms of ischemic injury are different in the steatotic and normal rat liver.

Authors:  M Selzner; H A Rüdiger; D Sindram; J Madden; P A Clavien
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

Review 2.  Liver enzyme alteration: a guide for clinicians.

Authors:  Edoardo G Giannini; Roberto Testa; Vincenzo Savarino
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

3.  Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease.

Authors:  W Ray Kim; Steven L Flamm; Adrian M Di Bisceglie; Henry C Bodenheimer
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

4.  Body mass index as a predictor of hepatic steatosis in living liver donors.

Authors:  M E Rinella; E Alonso; S Rao; P Whitington; J Fryer; M Abecassis; R Superina; S L Flamm; A T Blei
Journal:  Liver Transpl       Date:  2001-05       Impact factor: 5.799

5.  Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.

Authors:  Marta B Afonso; Pedro M Rodrigues; Tânia Carvalho; Marta Caridade; Paula Borralho; Helena Cortez-Pinto; Rui E Castro; Cecília M P Rodrigues
Journal:  Clin Sci (Lond)       Date:  2015-06-15       Impact factor: 6.124

6.  Toll-like receptor 4 is a key mediator of murine steatotic liver warm ischemia/reperfusion injury.

Authors:  Justin D Ellett; Zachary P Evans; Carl Atkinson; Michael G Schmidt; Rick G Schnellmann; Kenneth D Chavin
Journal:  Liver Transpl       Date:  2009-09       Impact factor: 5.799

Review 7.  Nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Vincent W-S Wong; Valerio Nobili; Christopher P Day; Silvia Sookoian; Jacquelyn J Maher; Elisabetta Bugianesi; Claude B Sirlin; Brent A Neuschwander-Tetri; Mary E Rinella
Journal:  Nat Rev Dis Primers       Date:  2015-12-17       Impact factor: 52.329

8.  Risk factors for primary dysfunction after liver transplantation--a multivariate analysis.

Authors:  R J Ploeg; A M D'Alessandro; S J Knechtle; M D Stegall; J D Pirsch; R M Hoffmann; T Sasaki; H W Sollinger; F O Belzer; M Kalayoglu
Journal:  Transplantation       Date:  1993-04       Impact factor: 4.939

Review 9.  Expanded criteria donors.

Authors:  Sandy Feng; Jennifer C Lai
Journal:  Clin Liver Dis       Date:  2014-08       Impact factor: 6.126

Review 10.  Questions and controversies: the role of necroptosis in liver disease.

Authors:  Lily Dara; Zhang-Xu Liu; Neil Kaplowitz
Journal:  Cell Death Discov       Date:  2016-12-05
View more
  12 in total

1.  Receptor-Interacting Serine/Threonine-Protein Kinase 3 (RIPK3)-Mixed Lineage Kinase Domain-Like Protein (MLKL)-Mediated Necroptosis Contributes to Ischemia-Reperfusion Injury of Steatotic Livers.

Authors:  Hong-Min Ni; Xiaojuan Chao; Joshua Kaseff; Fengyan Deng; Shaogui Wang; Ying-Hong Shi; Tiangang Li; Wen-Xing Ding; Hartmut Jaeschke
Journal:  Am J Pathol       Date:  2019-04-23       Impact factor: 4.307

2.  Clear mortality gap caused by graft macrosteatosis in Chinese patients after cadaveric liver transplantation.

Authors:  Zhengtao Liu; Wenchao Wang; Li Zhuang; Jingfeng Liu; Shuping Que; Dan Zhu; Linfang Dong; Jian Yu; Lin Zhou; Shusen Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

Review 3.  Liver ischaemia-reperfusion injury: a new understanding of the role of innate immunity.

Authors:  Hirofumi Hirao; Kojiro Nakamura; Jerzy W Kupiec-Weglinski
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-11-26       Impact factor: 46.802

4.  One-year chronic toxicity evaluation of single dose intravenously administered silica nanoparticles in mice and their Ex vivo human hemocompatibility.

Authors:  Raziye Mohammadpour; Darwin L Cheney; Jason W Grunberger; Mostafa Yazdimamaghani; Jolanta Jedrzkiewicz; Kyle J Isaacson; Marina A Dobrovolskaia; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2020-05-25       Impact factor: 9.776

Review 5.  Therapeutics administered during ex vivo liver machine perfusion: An overview.

Authors:  Julianna E Buchwald; Jing Xu; Adel Bozorgzadeh; Paulo N Martins
Journal:  World J Transplant       Date:  2020-01-18

Review 6.  Necroptotic Cell Death in Liver Transplantation and Underlying Diseases: Mechanisms and Clinical Perspective.

Authors:  Shaojun Shi; Monique M A Verstegen; Laura Mezzanotte; Jeroen de Jonge; Clemens W G M Löwik; Luc J W van der Laan
Journal:  Liver Transpl       Date:  2019-07       Impact factor: 5.799

Review 7.  Necroptosis in Cholangiocarcinoma.

Authors:  Samantha Sarcognato; Iris E M de Jong; Luca Fabris; Massimiliano Cadamuro; Maria Guido
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

Review 8.  Necroptosis in Hepatosteatotic Ischaemia-Reperfusion Injury.

Authors:  Raji Baidya; Darrell H G Crawford; Jérémie Gautheron; Haolu Wang; Kim R Bridle
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

9.  Monoacylglycerol Acyltransferase 1 Knockdown Exacerbates Hepatic Ischemia/Reperfusion Injury in Mice With Hepatic Steatosis.

Authors:  Kim H H Liss; Shelby E Ek; Andrew J Lutkewitte; Terri A Pietka; Mai He; Priya Skaria; Eric Tycksen; Daniel Ferguson; Valerie Blanc; Mark J Graham; Angela M Hall; Mitchell R McGill; Kyle S McCommis; Brian N Finck
Journal:  Liver Transpl       Date:  2020-10-22       Impact factor: 5.799

10.  Computational Modeling of Oxidative Stress in Fatty Livers Elucidates the Underlying Mechanism of the Increased Susceptibility to Ischemia/Reperfusion Injury.

Authors:  Jana Schleicher; Uta Dahmen
Journal:  Comput Struct Biotechnol J       Date:  2018-11-01       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.